Hospital
Palomar Health
Palomar Health was paid $144.14M by Medicaid between Jan 2018 and Dec 2024, across 324 billing codes. Its largest line is 0450, Emergency room services — 14% of everything it billed.
33Billing provider infoPALOMAR HEALTH
ESCONDIDO, CA 92029
ESCONDIDO, CA 92029
33aNPI1457321317assigned 01/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$144.14M
24GClaims1,459,443
24DCodes billed324
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#10 of 410
Median peer was paid$6.90M
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 209,605 | $26.52M | |
| 2019 | 190,272 | $20.33M | |
| 2020 | 169,396 | $18.35M | |
| 2021 | 187,723 | $16.85M | |
| 2022 | 241,562 | $20.19M | |
| 2023 | 253,107 | $21.26M | |
| 2024incomplete | 207,778 | $20.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 14% | 57,030 | 50,256 | $19.83M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 66,541 | 60,548 | $19.72M |
| J3490 | Unclassified drugs | 13% | 104,493 | 47,217 | $18.72M |
| 80048 | Basic metabolic panel (calcium, ionized) | 6.3% | 72,006 | 63,095 | $9.04M |
| 80053 | Comprehensive metabolic panel | 6.2% | 36,296 | 33,513 | $8.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.4% | 18,315 | 16,998 | $4.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 12,964 | 11,963 | $3.87M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.4% | 11,686 | 11,279 | $3.48M |
| 0250 | 1.9% | 47,759 | 17,962 | $2.72M | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.8% | 14,173 | 12,615 | $2.64M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 16,338 | 15,596 | $2.52M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 10,593 | 10,256 | $2.40M |
312 more codes
| 99499 | 1.4% | 18,767 | $2.03M | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.3% | 10,959 | $1.91M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,716 | $1.42M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 52,731 | $1.36M |
| 71045 | Radiologic examination, chest; single view | <1% | 36,630 | $1.28M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,601 | $1.16M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 9,965 | $1.08M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 8,073 | $1.04M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 7,255 | $1.03M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 80,084 | $999K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,391 | $928K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 16,367 | $904K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,383 | $903K |
| 97139 | <1% | 18,438 | $870K | |
| 81001 | <1% | 41,847 | $712K | |
| 80076 | <1% | 31,845 | $657K | |
| 0206 | <1% | 413 | $629K | |
| 84703 | <1% | 25,307 | $609K | |
| 0300 | <1% | 1,428 | $607K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,734 | $603K |
| 59025 | Fetal non-stress test | <1% | 10,824 | $578K |
| 73562 | <1% | 3,339 | $511K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,309 | $511K |
| 72131 | <1% | 3,491 | $502K | |
| 0121 | <1% | 291 | $495K | |
| 84702 | <1% | 6,244 | $494K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,704 | $488K |
| 76801 | <1% | 5,202 | $476K | |
| 73610 | <1% | 2,642 | $466K | |
| 0270 | <1% | 9,999 | $465K | |
| 84484 | <1% | 33,980 | $463K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,131 | $458K |
| 73630 | <1% | 3,032 | $449K | |
| 73030 | <1% | 2,444 | $444K | |
| 73130 | <1% | 2,163 | $414K | |
| 0171 | Inj, epinephrine (belcher) | <1% | 666 | $406K |
| 83690 | <1% | 36,584 | $405K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,983 | $399K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,340 | $394K |
| 0762 | <1% | 895 | $393K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,039 | $391K |
| 72128 | <1% | 2,867 | $378K | |
| 0761 | <1% | 5,114 | $369K | |
| G0378 | Hospital observation service, per hour | <1% | 1,324 | $362K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,291 | $360K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,004 | $353K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,414 | $352K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,936 | $351K |
| Z7502 | <1% | 9,984 | $344K | |
| 85027 | <1% | 30,415 | $340K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,237 | $338K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,120 | $334K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,967 | $316K |
| 81003 | <1% | 16,090 | $312K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,090 | $312K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,093 | $307K |
| 97799 | <1% | 5,671 | $291K | |
| 93971 | <1% | 2,764 | $261K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,237 | $255K |
| 0350 | <1% | 365 | $250K | |
| 87077 | <1% | 7,311 | $237K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,162 | $224K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,503 | $218K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,274 | $213K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,886 | $206K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,251 | $203K |
| 70486 | <1% | 1,261 | $192K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,541 | $192K |
| 73110 | <1% | 1,422 | $187K | |
| 93970 | <1% | 1,468 | $186K | |
| 86901 | <1% | 8,888 | $185K | |
| 70498 | <1% | 1,521 | $184K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,966 | $169K |
| 0760 | <1% | 1,267 | $162K | |
| 70496 | <1% | 1,322 | $156K | |
| 0260 | <1% | 3,323 | $155K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,803 | $153K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 10,669 | $151K |
| 73080 | <1% | 810 | $140K | |
| 97750 | <1% | 1,366 | $138K | |
| 74018 | <1% | 1,365 | $134K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,501 | $133K |
| 87040 | <1% | 4,300 | $123K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 860 | $119K |
| 73502 | <1% | 1,096 | $115K | |
| 0122 | <1% | 40 | $112K | |
| 93976 | <1% | 667 | $112K | |
| 72100 | <1% | 902 | $112K | |
| 0120 | <1% | 18 | $102K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,274 | $102K |
| 87503 | <1% | 2,202 | $102K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,596 | $98K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 343 | $94K |
| 73590 | <1% | 954 | $93K | |
| 83880 | <1% | 6,244 | $92K | |
| 82550 | <1% | 6,892 | $89K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 891 | $85K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,706 | $80K |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 253 | $80K |
| 83605 | <1% | 7,310 | $79K | |
| 87186 | <1% | 5,166 | $78K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 512 | $77K |
| 83735 | <1% | 10,065 | $76K | |
| 0410 | <1% | 427 | $76K | |
| 74022 | <1% | 887 | $74K | |
| 85610 | <1% | 14,440 | $71K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,646 | $70K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,362 | $69K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,162 | $64K |
| 0730 | <1% | 422 | $63K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,312 | $63K |
| 90715 | <1% | 1,488 | $62K | |
| 85379 | <1% | 5,616 | $59K | |
| 86308 | <1% | 418 | $59K | |
| 71250 | <1% | 722 | $56K | |
| 0710 | <1% | 675 | $56K | |
| 85730 | <1% | 7,456 | $52K | |
| 86885 | <1% | 4,605 | $52K | |
| 76770 | <1% | 471 | $49K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 882 | $48K |
| 73140 | <1% | 133 | $44K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,441 | $41K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 707 | $40K |
| 86140 | <1% | 4,602 | $40K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 60 | $39K |
| 87070 | <1% | 867 | $39K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,504 | $38K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,221 | $37K |
| 0370 | <1% | 251 | $37K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 983 | $36K |
| 0320 | <1% | 500 | $35K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,639 | $34K |
| 0360 | <1% | 85 | $34K | |
| 0451 | <1% | 610 | $33K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 138 | $33K |
| 94760 | <1% | 7,575 | $32K | |
| 0420 | <1% | 338 | $32K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,874 | $32K |
| 86900 | <1% | 4,846 | $31K | |
| 82962 | <1% | 2,779 | $31K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 804 | $29K |
| 0258 | <1% | 4,541 | $28K | |
| 82553 | <1% | 506 | $28K | |
| Z7610 | <1% | 3,102 | $28K | |
| 95811 | <1% | 38 | $27K | |
| 97014 | <1% | 224 | $26K | |
| 76870 | <1% | 363 | $26K | |
| 0255 | <1% | 2,612 | $26K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,869 | $26K |
| 73090 | <1% | 320 | $25K | |
| 84100 | <1% | 3,270 | $25K | |
| 87420 | <1% | 285 | $24K | |
| 97116 | <1% | 2,725 | $24K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,663 | $21K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 123 | $21K |
| 84145 | <1% | 1,483 | $20K | |
| 85652 | <1% | 3,420 | $20K | |
| 82805 | <1% | 936 | $20K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 861 | $19K |
| 96376 | <1% | 1,032 | $19K | |
| 73560 | <1% | 187 | $19K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,768 | $19K |
| 85007 | <1% | 2,918 | $18K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 280 | $18K |
| 0430 | <1% | 160 | $17K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 265 | $16K |
| 97597 | <1% | 185 | $16K | |
| 51701 | <1% | 166 | $15K | |
| 76813 | <1% | 126 | $15K | |
| 87081 | <1% | 574 | $15K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,202 | $14K |
| Z9725 | <1% | 313 | $13K | |
| 87210 | <1% | 451 | $13K | |
| 71101 | <1% | 43 | $13K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 92 | $13K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 39 | $13K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 663 | $13K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 94 | $12K |
| 80061 | Lipid panel | <1% | 2,111 | $12K |
| 73060 | <1% | 66 | $11K | |
| 0489 | <1% | 47 | $10K | |
| 0400 | <1% | 66 | $10K | |
| 86920 | <1% | 178 | $10K | |
| 97161 | <1% | 738 | $10K | |
| 97166 | <1% | 397 | $9K | |
| 93017 | <1% | 145 | $9K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 24 | $9K |
| 82140 | <1% | 884 | $9K | |
| 94644 | <1% | 604 | $9K | |
| 0272 | <1% | 2,160 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,544 | $8K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,358 | $8K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,103 | $7K |
| 82010 | <1% | 871 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 930 | $7K |
| 97162 | <1% | 457 | $6K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,021 | $6K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 600 | $6K |
| 93798 | <1% | 120 | $6K | |
| 0949 | <1% | 67 | $6K | |
| 72110 | <1% | 26 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,880 | $6K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 494 | $6K |
| 94645 | <1% | 658 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 74 | $5K |
| 85576 | <1% | 284 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 660 | $5K |
| 84439 | <1% | 821 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 804 | $4K |
| 97163 | <1% | 48 | $4K | |
| 92526 | <1% | 194 | $4K | |
| 82248 | <1% | 727 | $4K | |
| 87205 | <1% | 726 | $4K | |
| 0301 | <1% | 82 | $4K | |
| G0288 | Reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery | <1% | 78 | $4K |
| 82728 | <1% | 731 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 172 | $4K |
| 84550 | <1% | 526 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 283 | $3K |
| 0324 | <1% | 43 | $3K | |
| 70491 | <1% | 29 | $3K | |
| 12001 | <1% | 39 | $3K | |
| 80164 | <1% | 166 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 387 | $3K |
| 10060 | <1% | 28 | $3K | |
| 71020 | <1% | 49 | $3K | |
| 87147 | <1% | 102 | $3K | |
| 72050 | <1% | 12 | $3K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 29 | $3K |
| 88342 | <1% | 91 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 194 | $2K |
| 85384 | <1% | 220 | $2K | |
| 97165 | <1% | 134 | $2K | |
| 87324 | <1% | 146 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 50 | $2K |
| 83615 | <1% | 428 | $2K | |
| 88313 | <1% | 113 | $2K | |
| 29125 | <1% | 30 | $2K | |
| 86780 | <1% | 239 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 24 | $2K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 68 | $2K |
| 82607 | <1% | 365 | $2K | |
| 82247 | <1% | 95 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 932 | $2K |
| 87449 | <1% | 126 | $2K | |
| 87177 | <1% | 112 | $2K | |
| Z7500 | <1% | 52 | $2K | |
| 86141 | <1% | 72 | $2K | |
| 71010 | <1% | 47 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 199 | $2K |
| 82570 | <1% | 328 | $2K | |
| 12002 | <1% | 12 | $2K | |
| 82565 | <1% | 282 | $1K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 64 | $1K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 107 | $1K |
| 92610 | <1% | 68 | $1K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 51 | $1K |
| 84450 | <1% | 261 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 25 | $1K |
| 87088 | <1% | 41 | $1K | |
| 80047 | <1% | 48 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $1K |
| 84156 | <1% | 299 | $1K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 14 | $1K |
| 82746 | <1% | 172 | $925.40 | |
| 98960 | <1% | 83 | $849.43 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 413 | $847.58 |
| 36415 | Collection of venous blood by venipuncture | <1% | 895 | $831.47 |
| 0310 | <1% | 14 | $812.75 | |
| 84466 | <1% | 209 | $784.06 | |
| 76376 | <1% | 50 | $765.05 | |
| 80178 | <1% | 61 | $761.46 | |
| 84460 | <1% | 133 | $754.55 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $742.50 |
| 87075 | <1% | 84 | $718.92 | |
| 0100U | <1% | 22 | $672.61 | |
| 84132 | <1% | 273 | $672.09 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 184 | $653.85 |
| 12011 | <1% | 14 | $611.84 | |
| 97016 | <1% | 41 | $579.75 | |
| 83540 | <1% | 209 | $564.24 | |
| 51702 | <1% | 12 | $559.81 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 50 | $485.51 |
| 90686 | <1% | 47 | $470.42 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 29 | $451.00 |
| 87045 | <1% | 12 | $427.82 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 72 | $381.26 |
| 84520 | <1% | 88 | $372.78 | |
| 0271 | <1% | 93 | $336.15 | |
| 87427 | <1% | 13 | $335.85 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 62 | $324.41 |
| 87046 | <1% | 14 | $259.92 | |
| 83930 | <1% | 72 | $253.85 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 19 | $250.50 |
| 84146 | <1% | 29 | $201.56 | |
| 82947 | <1% | 19 | $196.13 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 27 | $169.89 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 48 | $137.72 |
| 84403 | <1% | 14 | $136.55 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 12 | $94.62 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 88 | $81.75 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 85 | $77.18 |
| 72170 | <1% | 13 | $66.50 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 30 | $40.11 |
| S0028 | Injection, famotidine, 20 mg | <1% | 57 | $38.61 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 12 | $15.20 |
| 36430 | 0% | 19 | $0.00 | |
| 87340 | 0% | 14 | $0.00 | |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 14 | $0.00 |
| 84112 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 49 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSEN, DIANE (PRESIDENT AND CEO)
Parent organizationPALOMAR HEALTH
| Provider | Location | Paid |
|---|---|---|
| Palomar Health | Poway, CA | $46.68M |
| Palomar Health | Escondido, CA | $42.20M |
| MT Graham Regional Medical Center INC | Safford, AZ | $5.92M |
| Palomar Health | San Marcos, CA | $2.84M |
| Palomar Health | Escondido, CA | $1.20M |
| Palomar Health | Poway, CA | $528K |
| Speech Center of Southern Arizona | Tucson, AZ | $281K |
| Palomar Health | Escondido, CA | $40K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.